Twist Bioscience (NASDAQ:TWST) Issues Quarterly Earnings Results

Key Points

• Twist Bioscience reported an EPS of ($0.47), exceeding analyst expectations by $0.07 as they had anticipated ($0.54).
• The company faces financial challenges with a negative net margin of 54.98% and a negative return on equity of 33.48%.
• Insider trading reports show both the CFO and CEO selling shares, with insider ownership now at 3.01% of the company.

Twist Bioscience (NASDAQ:TWST - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07, Zacks reports. The company had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.

Twist Bioscience Trading Up 2.6%

NASDAQ TWST traded up $0.64 during mid-day trading on Friday, reaching $25.64. 1,968,975 shares of the stock were exchanged, compared to its average volume of 1,145,031. The stock has a market cap of $1.55 billion, a P/E ratio of -17.68 and a beta of 2.36. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 4.24. Twist Bioscience has a one year low of $24.28 and a one year high of $55.33. The stock has a 50 day simple moving average of $34.55 and a 200-day simple moving average of $38.26.

Insider Buying and Selling at Twist Bioscience

In related news, COO Patrick John Finn sold 1,877 shares of the company's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total transaction of $55,840.75. Following the sale, the chief operating officer owned 240,783 shares in the company, valued at $7,163,294.25. This represents a 0.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Emily M. Leproust sold 1,678 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $35.76, for a total value of $60,005.28. Following the sale, the chief executive officer directly owned 645,782 shares of the company's stock, valued at $23,093,164.32. This represents a 0.26% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,109 shares of company stock valued at $425,962. 3.01% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. increased its stake in shares of Twist Bioscience by 4.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company's stock valued at $36,629,000 after acquiring an additional 37,577 shares in the last quarter. Intech Investment Management LLC grew its holdings in Twist Bioscience by 18.9% in the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company's stock worth $1,135,000 after purchasing an additional 4,591 shares during the period. Royal Bank of Canada increased its stake in Twist Bioscience by 11.8% in the first quarter. Royal Bank of Canada now owns 40,373 shares of the company's stock valued at $1,585,000 after purchasing an additional 4,254 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Twist Bioscience by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company's stock valued at $2,765,000 after purchasing an additional 3,181 shares during the period.

Wall Street Analyst Weigh In

Several research firms recently commented on TWST. Evercore ISI set a $46.00 target price on shares of Twist Bioscience in a research report on Monday. JPMorgan Chase & Co. dropped their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. The Goldman Sachs Group reduced their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Cowen restated a "buy" rating on shares of Twist Bioscience in a report on Monday. Finally, Barclays lowered their target price on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $49.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.